(also known as Mustafa Abdusalam Alqadhi) has an extensive publication record focused on medicinal chemistry, specifically in the development of kinase inhibitors and advanced drug delivery systems.
Doctor of Pharmacy (PharmD): He holds a PharmD degree, which provided him with advanced clinical and pharmacological training.
PhD Studies: He has been involved in advanced postgraduate research at the Faculty of Pharmacy, Cairo University (Egypt), specifically within the Department of Pharmaceutical Chemistry. His work ther
Academic Affiliation: He is a researcher at the Faculty of Pharmacy, Cairo University in Egypt, where he has been actively involved in advanced drug discovery projects.
Research Leadership: He leads the Mustafa Abdusalam Alqadhi Lab, which focuses on "bench-to-bedside" research, particularly in the development of small molecule inhibitors.
His work is characterized by the use of modern chemical techniques to improve existing drug classes:
Kinase Inhibitors: He has specialized in the synthesis of Pyrazolo[1,5-a]pyrimidine scaffolds, which are used to develop TRK and CK2 kinase inhibitors for cancer therapy.
Drug Repurposing: A major part of his recent research involves using nanoemulsions to repurpose antifungal agents like Miconazole into effective anticancer treatments.
His research primarily centers on finding more effective ways to treat cancer and prevent infections:
Kinase Inhibitors: He specializes in designing and synthesizing new biologically active compounds targeting different kinase inhibitors (such as CK2 and TRK) for use in various types of cancer.
Nanotechnology & Drug Repurposing: A major part of his work involves using olive oil-based nanoemulsions to repurpose antifungal agents like Miconazole for anticancer therapy.
Medical Engineering: He has researched antimicrobial coatings for medical implants, specifically the controlled release of Ketoconazole from titanium to prevent post-surgical infections.
Kinase Inhibitors: Key studies include reviews on pyrazolo[1, 5-a]pyrimidine scaffolds (2025), Tropomyosin Receptor Kinases (TRKs) (2023), and CK2 inhibitors (2024). He has also synthesized 7-Aryl-2-Methyl-3-Substituted Pyrazolo{1,5-a}Pyrimidines (2023) and quinoxaline-based inhibitors (2025).
Targeted Therapies: Investigations into thieno-pyrimidine derivatives for breast cancer (2025) and the repurposing of Miconazole via nanoemulsion (2024).
Drug Delivery: Development of controlled-release systems for Ketoconazole to prevent prosthetic joint infections (2024)
